AMR Benchmark homepage

Feature - 23 Jan 2018

The superbugs can be stopped - if we put good ideas into action

The 2018 AMR Benchmark compares for the first time how a cross-section of the pharmaceutical industry is responding to the threat from drug-resistant infections. Executive Director, Jayasree K. Iyer, gives her take on the new research.

The AMR Benchmark: 1st report on pharma’s response to AMR

The Antimicrobial Resistance Benchmark compares how pharmaceutical companies are bringing AMR under control. It covers R&D, responsible manufacturing, access and stewardship.

Key finding

28 antibiotics for priority pathogens - two stand out

The pipelines captured in the Benchmark have 175 antimicrobial medicines targeting pathogens seen by WHO and CDC as the biggest AMR threats, including 28 antibiotic candidates in late stages of clinical development.

Key finding

Nine companies are tracking drug resistance

Curbing AMR depends on knowing where pathogens are developing resistance. Nine companies are running or supporting 19 AMR surveillance programmes across 147 countries.